(Q40349005)

19 September 2017

title

Insulin-like growth factor receptor I targeting in epithelial ovarian cancer (English)

1 reference

19 September 2017

1 reference

1 reference

2

Ilan Bruchim

1 reference

19 September 2017

Walter H Gotlieb

1

1 reference

19 September 2017

Jing Gu

3

1 reference

19 September 2017

Ying Shi

4

1 reference

19 September 2017

Anne Camirand

5

1 reference

19 September 2017

Marie-José Blouin

6

1 reference

19 September 2017

Yunhua Zhao

7

1 reference

19 September 2017

Michael N Pollak

8

1 reference

19 September 2017

language of work or name

English

0 references

publication date

21 November 2005

1 reference

19 September 2017

1 reference

19 September 2017

volume

100

1 reference

19 September 2017

issue

2

1 reference

19 September 2017

page(s)

389-396

1 reference

Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.048

The insulin-like growth factor insulin system in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.048

Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.048

The insulin-like growth factor system and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.048

The price of independence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.048

In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.048

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.048

Ovarian cancer: strategies for overcoming resistance to chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.048

Drug resistance reversal--are we getting closer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.048

Emerging treatments for ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.048

Treatment of ovarian cancer: new strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.048

Insulin-like growth factors and neoplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.048

Circulating levels of insulin-like growth factor-I and risk of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.048

Biological characterization of human epithelial ovarian carcinoma cells in primary culture: the insulin-like growth factor system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.048

Antisense oligonucleotide to insulin-like growth factor II induces apoptosis in human ovarian cancer AO cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.048

10.1016/J.YGYNO.2005.09.048

7 January 2021

Identifiers

DOI

1 reference

19 September 2017

1 reference